Description
Background information
Human cytomegalovirus (HCMV) is a member of the herpes virus group and belongs to the subfamily of beta-herpes viruses. Between 50 and 85% of human adults are infected with HCMV. Once infected, the virus persists in the organism. The infection is asymptomatic in healthy individuals but in immunocompromized patients HCMV can cause severe disease.
The pp65 protein (65 kDa lower matrix phosphoprotein), also known as glycoprotein 64 or UL83, is a virion tegument protein and the main component of the enveloped subviral particle. pp65 is an immunodominant target of CD4+ as well as CD8+ T cell responses to HCMV.
Applications
Antigen-specific T cells play a critical role in the regulation of immune responses and the elimination of virus-infected or malignant cells in the human body. Adoptive transfer of clinical-grade pp65-specific CD4+ and CD8+ T cells is a valuable tool for the treatment of HCMV infections after hematopoietic stem cell transplantation (SCT)1,2 and shows potential for solid organ transplantation (SOT).3
The in vitro stimulation of pp65-specific CD4+ and CD8+ T cells with MACS® GMP PepTivator HCMV pp65 causes the production of the effector cytokine IFN-gamma. The secretion of IFN-gamma then permits the enrichment of pp65-specific effector/memory T cells with the use of the CliniMACS Cytokine Capture System (IFN-gamma).4,5
Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
Disclaimer
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
Overview
The MACS GMP PepTivator HCMV pp65 is a peptide pool that consists mainly of 15-mer peptides with eleven amino-acids overlap. It has been developed for efficient in vitro stimulation and subsequent isolation of HCMV pp65-specific CD4+ and CD8+ T cells.
